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initiated on an antidepressant or antihypertensive medicine. Rather than providing a 
sample (or starter pack), the GP prescribed a reduced quantity of the chosen medica-
tion for dispensing by a community pharmacy. Action research cycles allowed local 
changes to the initial protocol by study practitioners. Prescription dispensing histories 
were obtained to track time between starter pack and full quantity dispensing. GP 
follow-up appointments were tracked via practice appointment systems. Practitioner 
and patient satisfaction surveys were conducted. RESULTS: Two primary care general 
practices with a pharmacy nearby participated. Thirty-one patients received 32 starter 
prescriptions. The average age was 43.9 years (SD 16.7, range 23–80) with 44% being 
male. Twenty-nine starter prescriptions were dispensed with 17 tracked to full pre-
scription dispensing. Thirteen (45%) prescriptions were for antihypertensives. Study 
prescriptions were always dispensed as a generic brand, whenever one was available. 
This occurred for 11 (69%) of antidepressants and 3 (23%) of antihypertensives. 
Twenty-eight patients (87%) made a follow-up appointment, however 11 were outside 
the time window deemed appropriate for completion of the starter pack. Survey 
responses showed all patients were satisﬁed with information provided by their GP 
and pharmacist, and agreed starter packs facilitate trial of a new medicine (new to 
the patient, not necessarily new to the market). Patients, GPs and pharmacists 
approved of the pilot protocol. CONCLUSIONS: Community pharmacist involve-
ment in dispensing starter packs was practical and acceptable to practitioners and 
patients. A similar model could be tailored for other jurisdictions based on local 
requirements to avoid adverse consequences associated with current systems of pre-
scriber-distributed free prescription medicine samples.
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OBJECTIVES: To perform a comparative assessment of the medical beneﬁt of ASA           
for secondary prevention of cardiovascular events in patients with peripheral arterial 
disease (PAD) using existing published data. METHODS: In a systematic literature    
search up to January 2009 according to the methodological guidance documents of 
the IQWiG relevant publications of RCTs and systematic reviews were detected. Study 
characteristics and results were extracted and presented in evidence tables. RESULTS: 
Overall 16 studies (18 publications) were included in the analyses. The methodological 
approaches of the studies were heterogeneous and especially the older studies have 
some major methodological restrictions. There was no statistically signiﬁcant differ-
ence of ASA compared to all other alternatives incl. placebo with regard to overall 
mortality, risk of myocardial infarction or stroke. A statistically signiﬁcant disadvan-
tage compared to clopidogrel was shown for vascular mortality and a combined end-
point of vascular mortality, myocardial infarction and stroke. Using this combined 
endpoint a signiﬁcant advantage of ASS compared to placebo was shown. With regard 
to adverse events ASA had a tendency to higher discontinuation rates and a higher 
incidence of gastrointestinal problems. CONCLUSIONS: Overall the analyses using    
the IQWiG’s approach for the assessment of medical beneﬁts showed no advantage 
of a monotherapy with ASA compared to other alternatives incl. placebo for secondary 
prevention of cardiovascular events in patients with PAD. The currently available 
published data do not justify a general recommendation of ASA in PAD patients with 
regard to cardiovascular endpoints. The analysis shows the need also to assess the 
beneﬁt of long time used pharmaceuticals to avoid a potential ritualized and inefﬁcient 
use. Furthermore the results are necessary in the IQWiG’s assessments of more innova-
tive technologies to have valid information of standard comparators, too.
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OBJECTIVES: Elevated low-density lipoprotein cholesterol (LDL-C) is the primary        
treatment target for patients at risk of coronary heart disease (CHD). Low high-density 
lipoprotein cholesterol (HDL-C) and elevated triglycerides (TG) are also risk factors 
for CHD, however often remain unaddressed. This cross-sectional study attempted to 
identify the extent of prevalence of low HDL-C and/or elevated TG combined with 
elevated LDL-C among patients treated with lipid modifying therapy (LMT) in 
Hungary. METHODS: Using 8,768 we identiﬁed patients who were at least 35 years           
of age treated with a LMT for at least 6 weeks and also had a complete lipid proﬁle 
within the past 6 weeks. Patients were considered to be at high CV risk if they had a 
history of CV disease, or type II diabetes or 10 year CHD risk q 20%. Current Euro-
pean Society of Cardiology guidelines were used to deﬁne lipid threshold levels. 
RESULTS: In a sample of 1,373 high CV risk patients treated with LMT, slightly over              
80% patients experienced q1 lipid abnormality. Among these, 64% had elevated 
LDL-C while approximately 37% had elevated LDL-C along with HDL-C and/or TG 
abnormality. Nearly 33% of treated high risk patient experiencing lipid abnormality 
had low HLD-C level and 56% experienced elevated TG problem. Approximately 
12% of the sample with any lipid abnormality had all 3 lipid abnormalities. CON-
CLUSIONS: In this cross-sectional study of Hungarian high CV risk patients treated           
primarily with statins, ~80% of all patients with at least one lipid abnormalities 
experienced elevated LDL-C. In addition, 45% of treated high CV risk patient still 
had TG or HDL (or both) lipid abnormalities who could potentially beneﬁt from other 
lipid-modifying therapies in addition to statins.
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OBJECTIVES: To assess the ﬁrst Japanese guideline for the management of stroke 
developed in 2004 (Int J Stroke 2007; 2: 133–135) by a formal method. METHODS: 
This guideline was critically appraised using three instruments of AGREE, COGS and 
Shaneyfelt by independent reviewers from the developers. They consisted of 22 stroke 
physicians, 8 general physicians, and 11 nurses. Best evaluation corresponds to 100% 
of response rate. RESULTS: A response rate was ranging from 66 to 91% with regard 
to each of many checklists . There was no distinction among the appraisal instruments. 
Among those, the dimensions of scope/purpose (89%), rigor of development (83%), 
and clarity/presentation (76%) were highly approved in integrity of the guideline, yet, 
relatively lower in editorial independence (71%), stakeholder involvement (70%), and 
applicability (69%). Nurses tended to provide a more faborable response. CONCLU-
SIONS: The Japanese guideline for the management of stroke was ﬁrst formally 
evaluated and turned out to be fairly acceptable.
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OBJECTIVES: According to JNC 7 guidelines, most hypertensive patients require 
multiple drugs—as individual agents or ﬁxed-dose combinations (FDCs)—to achieve 
blood pressure goals. They suggest that FDCs may be simplest, most convenient, and 
most cost-effective. However, usage patterns for FDCs are not fully known. Our 
objective was to explore prescription treatment patterns for monotherapy and com-
bination therapy for US adults with diagnosed hypertension. METHODS: Data were 
obtained from the 2007 US National Health and Wellness Survey (NHWS) quarters 
1–3. The NHWS is an annual, nationally representative, Internet-based survey of 
adults (q18 years). Respondents were asked about their hypertension and its treatment. 
Drugs reported were compared for monotherapy versus combinations (single agents 
and/or FDCs) and grouped by class: angiotensin II receptor blockers (ARBs), A- or B-
blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) 
inhibitors, and diuretics including hydrochlorothiazide. RESULTS: Respondents 
 numbered 19,874. Of 16,495 (83%) who reported using prescription therapy, 215 
(1%) responded ambiguously, whereas 7705 (47%) received single-agent mono-
therapy: an ACE inhibitor (2828 [37%] of 7705), a B-blocker (1796 [23%]), or 
something else. The remaining 8575 (52% of 16,495) patients received combination 
therapies: two single agents with no FDC (3516 [41%] of 8575), three or more single 
agents with no FDC (2285 [27%]), an FDC alone (1517 [18%]), an FDC plus one 
agent (744 [9%]), an FDC plus two single agents (432 [5%]), or other (81 [1%]). 
Common FDC-only therapies were an ARB  hydrochlorothiazide (713 [47%] of 
1517 patients), and an ACE inhibitor  CCB (384 [25%]). CONCLUSIONS: More 
than half of the hypertensive respondents to the NHWS received at least two antihy-
pertensive agents, with the majority receiving multiple individual products instead of 
an FDC product. Understanding the factors contributing to this use proﬁle, such as 
cost, availability, convenience, and compliance, requires further exploration.
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OBJECTIVES: The advantage of selective inhibitors of cyclo-oxygenase-2 (COX-2 
NSAIDs) over other traditional non-selective NSAIDs (tNSAIDs) is that the risks of 
serious upper gastro-intestinal events are lower. This study aimed to assess the GI 
toxicity of tNSAIDs in comparison with COX-2 NSAIDs, comparing different epide-
miological designs. METHODS: Incident users of NSAIDs in Tayside, Scotland, 
UK were identiﬁed from January 1,2005 to 2007 from the population databases of 
the Health Informatics Centre. Confounders included age, gender, deprivation, co-
morbidity and prescribed ulcer healing drugs, and aspirin. Analysis of upper GI 
 hospitalisation utilised standard multiple regression analysis using Cox PH model; 
adjustment for propensity scores; and the Self Controlled Case Series (SCCS). 
RESULTS: From a total cohort of 68,736 users of NSAIDs, there were 1.5% 
(n  982) receiving a COX-2 NSAID, with Celecoxib having the highest proportion 
81.5% (n  800). Differences in baseline characteristics indicated that prescribing of 
COX-2 NSAIDs was more prevalent in the elderly, those who received aspirin, ulcer 
healing drugs and with a history of other GI hospitalisations. In the standard adjusted 
Cox PH model, those in receipt of COX-2 NSAIDs compared with other tNSAIDs 
had higher risk of upper GI events (HR  1.95, 95% CI 1.19, 3.17). After adjustment 
